Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy

Andrea Marzi, Hideki Ebihara, Julie Callison, Allison Groseth, Kinola J. Williams, Thomas Geisbert, Heinz Feldmann

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

For Ebola virus (EBOV), 4 different species are known: Zaire, Sudan, Côte d'Ivoire, and Reston ebolavirus. The newly discovered Bundibugyo ebolavirus has been proposed as a 5th species. So far, no cross-neutralization among EBOV species has been described, aggravating progress toward cross-species protective vaccines. With the use of recombinant vesicular stomatitis virus (rVSV)-based vaccines, guinea pigs could be protected against Zaire ebolavirus (ZEBOV) infection only when immunized with a vector expressing the homologous, but not a heterologous, EBOV glycoprotein (GP). However, infection of guinea pigs with nonadapted wild-type strains of the different species resulted in full protection of all animals against subsequent challenge with guinea pig-adapted ZEBOV, showing that cross-species protection is possible. New vectors were generated that contain EBOV viral protein 40 (VP40) or EBOV nucleoprotein (NP) as a second antigen expressed by the same rVSV vector that encodes the heterologous GP. After applying a 2-dose immunization approach, we observed an improved cross-protection rate, with 5 of 6 guinea pigs surviving the lethal ZEBOV challenge if vaccinated with rVSV-expressing SEBOV-GP and -VP40. Our data demonstrate that cross-protection between the EBOV species can be achieved, although EBOV-GP alone cannot induce the required immune response.

Original languageEnglish (US)
JournalJournal of Infectious Diseases
Volume204
Issue numberSUPPL. 3
DOIs
StatePublished - Nov 1 2011
Externally publishedYes

Fingerprint

Ebola Vaccines
Ebolavirus
Vesicular Stomatitis
Democratic Republic of the Congo
Cross Protection
Glycoproteins
Guinea Pigs
Viral Proteins
Viruses
Vaccines
Sudan
Nucleoproteins

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. / Marzi, Andrea; Ebihara, Hideki; Callison, Julie; Groseth, Allison; Williams, Kinola J.; Geisbert, Thomas; Feldmann, Heinz.

In: Journal of Infectious Diseases, Vol. 204, No. SUPPL. 3, 01.11.2011.

Research output: Contribution to journalArticle

Marzi, Andrea ; Ebihara, Hideki ; Callison, Julie ; Groseth, Allison ; Williams, Kinola J. ; Geisbert, Thomas ; Feldmann, Heinz. / Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. In: Journal of Infectious Diseases. 2011 ; Vol. 204, No. SUPPL. 3.
@article{a4fcee693c414071819d34db6e7cc435,
title = "Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy",
abstract = "For Ebola virus (EBOV), 4 different species are known: Zaire, Sudan, C{\^o}te d'Ivoire, and Reston ebolavirus. The newly discovered Bundibugyo ebolavirus has been proposed as a 5th species. So far, no cross-neutralization among EBOV species has been described, aggravating progress toward cross-species protective vaccines. With the use of recombinant vesicular stomatitis virus (rVSV)-based vaccines, guinea pigs could be protected against Zaire ebolavirus (ZEBOV) infection only when immunized with a vector expressing the homologous, but not a heterologous, EBOV glycoprotein (GP). However, infection of guinea pigs with nonadapted wild-type strains of the different species resulted in full protection of all animals against subsequent challenge with guinea pig-adapted ZEBOV, showing that cross-species protection is possible. New vectors were generated that contain EBOV viral protein 40 (VP40) or EBOV nucleoprotein (NP) as a second antigen expressed by the same rVSV vector that encodes the heterologous GP. After applying a 2-dose immunization approach, we observed an improved cross-protection rate, with 5 of 6 guinea pigs surviving the lethal ZEBOV challenge if vaccinated with rVSV-expressing SEBOV-GP and -VP40. Our data demonstrate that cross-protection between the EBOV species can be achieved, although EBOV-GP alone cannot induce the required immune response.",
author = "Andrea Marzi and Hideki Ebihara and Julie Callison and Allison Groseth and Williams, {Kinola J.} and Thomas Geisbert and Heinz Feldmann",
year = "2011",
month = "11",
day = "1",
doi = "10.1093/infdis/jir348",
language = "English (US)",
volume = "204",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy

AU - Marzi, Andrea

AU - Ebihara, Hideki

AU - Callison, Julie

AU - Groseth, Allison

AU - Williams, Kinola J.

AU - Geisbert, Thomas

AU - Feldmann, Heinz

PY - 2011/11/1

Y1 - 2011/11/1

N2 - For Ebola virus (EBOV), 4 different species are known: Zaire, Sudan, Côte d'Ivoire, and Reston ebolavirus. The newly discovered Bundibugyo ebolavirus has been proposed as a 5th species. So far, no cross-neutralization among EBOV species has been described, aggravating progress toward cross-species protective vaccines. With the use of recombinant vesicular stomatitis virus (rVSV)-based vaccines, guinea pigs could be protected against Zaire ebolavirus (ZEBOV) infection only when immunized with a vector expressing the homologous, but not a heterologous, EBOV glycoprotein (GP). However, infection of guinea pigs with nonadapted wild-type strains of the different species resulted in full protection of all animals against subsequent challenge with guinea pig-adapted ZEBOV, showing that cross-species protection is possible. New vectors were generated that contain EBOV viral protein 40 (VP40) or EBOV nucleoprotein (NP) as a second antigen expressed by the same rVSV vector that encodes the heterologous GP. After applying a 2-dose immunization approach, we observed an improved cross-protection rate, with 5 of 6 guinea pigs surviving the lethal ZEBOV challenge if vaccinated with rVSV-expressing SEBOV-GP and -VP40. Our data demonstrate that cross-protection between the EBOV species can be achieved, although EBOV-GP alone cannot induce the required immune response.

AB - For Ebola virus (EBOV), 4 different species are known: Zaire, Sudan, Côte d'Ivoire, and Reston ebolavirus. The newly discovered Bundibugyo ebolavirus has been proposed as a 5th species. So far, no cross-neutralization among EBOV species has been described, aggravating progress toward cross-species protective vaccines. With the use of recombinant vesicular stomatitis virus (rVSV)-based vaccines, guinea pigs could be protected against Zaire ebolavirus (ZEBOV) infection only when immunized with a vector expressing the homologous, but not a heterologous, EBOV glycoprotein (GP). However, infection of guinea pigs with nonadapted wild-type strains of the different species resulted in full protection of all animals against subsequent challenge with guinea pig-adapted ZEBOV, showing that cross-species protection is possible. New vectors were generated that contain EBOV viral protein 40 (VP40) or EBOV nucleoprotein (NP) as a second antigen expressed by the same rVSV vector that encodes the heterologous GP. After applying a 2-dose immunization approach, we observed an improved cross-protection rate, with 5 of 6 guinea pigs surviving the lethal ZEBOV challenge if vaccinated with rVSV-expressing SEBOV-GP and -VP40. Our data demonstrate that cross-protection between the EBOV species can be achieved, although EBOV-GP alone cannot induce the required immune response.

UR - http://www.scopus.com/inward/record.url?scp=80054753979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054753979&partnerID=8YFLogxK

U2 - 10.1093/infdis/jir348

DO - 10.1093/infdis/jir348

M3 - Article

VL - 204

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - SUPPL. 3

ER -